Global Transthyretin Amyloidosis Treatment Market

By Author: shubhammaximize8
Total Articles: 32
Comment this article

Global Transthyretin Amyloidosis Treatment Market size was valued US$ 37.88Mn. in 2019 and the total revenue is expected to grow at XX% from2019 to 2027, reaching nearly US$ XXMn.

The report study has analyzed the revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis.

Amyloidoses, range of protein disorders, are characterized by insoluble extracellular fibril deposits that get deposited in organs and cause organ dysfunction. Transthyretin is one such protein that can cause transthyretin amyloidosis. Treatments of amyloidosis are used to reduce the amyloidosis and limit amyloid protein production. It happens due to various causes like hereditary factors, bone marrow disorder, or even due to some other underlying sickness.

The transthyretin amyloidosis treatment market dynamics are thoroughly studied and explained in the MMR report, which helps to understand emerging market trends, drivers, restraints, opportunities, and challenges at the global and regional level for the TTR amyloidosis ...
... treatment market globally. The market is likely to experience robust development post the launch of transthyretin therapeutic drugs, primarily because of growing American African population, growing healthcare spending, and accelerating financial growth. On the flip side, lack of information on this condition and insufficiency of advanced diagnostic methods in middle income economies are significant TTR amyloidosis market barriers.

According to the American Society of Clinical Oncology report, nearby 4000 people in the US develop amyloidosis yearly and it is usually diagnosed between people aged 50 to 65 years. There are rare cases of people in their late 20 s being detected with amyloidosis. Therefore,with an upsurge in the ageing population, the market for transthyretin (TTR) amyloidosis treatment will also grow.

The MMR report covers the segments in the transthyretin amyloidosis treatment market such as treatment type, disease type, and distribution channel. Based on the disease type, hereditary transthyretin amyloidosis (hATTR) segment was valued US$ XX Mn. in 2019 and is expected to reach a value of US$ XX Mn by 2027, with a CAGR of XX.68% during the forecast period. The hATTR is caused by the misfolding of protein monomers resulting from the TTR. Mutations in the gene for TTR normally result in uncertainty of subsequent fibril formation and TTR. Hereditary transthyretin amyloidosis can be sub-classified into polyneuropathy, cardiomyopathy and mixed.

North America transthyretin amyloidosis treatment market was valued US$ XX Mn. in 2019 and is expected to reach a value of US$ XX Mn. by 2027, with a CAGR of XX.32% during 2019-2027. This is attributed to an increasing prevalence of amyloidosis between adults and the ageing & growing geriatric population, which is a significant cause for TTR disease. Such as, as per the ASCO Journal study in 2016, around 4,000 people develop amyloidosis yearly in the United States.

Europe stood as the second largest in the transthyretin amyloidosis treatment market thanks to the availability of advanced treatment services, a growing need for the better healthcare industry. Almost 60 new cases of TTR amyloidosis are recorded per year in the U.K, and the age-specific occurrence rate is among 5.1 and 12.8 per million yearly.

The MMR report also focuses on global major leading industry players of transthyretin amyloidosis treatment market providing information like company profiles, and revenue. Such as, in 2018, Alnylam Pharmaceuticals Company received the United StatesFDA (Food and Drug Administration) support for its ONPATTRO lipid complex injection RNA interference (RNAi) therapeutic - specified for the treatment of the polyneuropathy of hereditary TTR-mediated amyloidosis in adults.

The objective of the report is to present a comprehensive analysis of the Global Transthyretin Amyloidosis Treatment Marketincluding all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding Global Transthyretin Amyloidosis Treatment Marketdynamics, structure by analyzing the market segments and projects the Global Transthyretin Amyloidosis Treatment Marketsize. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Transthyretin Amyloidosis Treatment Market make the report investor’s guide.
Scope of the Global Transthyretin Amyloidosis Treatment Market

Global Transthyretin Amyloidosis Treatment Market, By Treatment Type

• Small molecules treatment
• RNAi therapy
• Organ transplantation
• Others
Global Transthyretin Amyloidosis Treatment Market, By Disease Type

• Hereditary Transthyretin Amyloidosis
o Polyneuropathy
o Cardiomyopathy
o Mixed
• Wild Type
Global Transthyretin Amyloidosis Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Specialty Pharmacies
• Retail Pharmacies
• Online Pharmacies
Global Transthyretin Amyloidosis Treatment Market, By Region

• North America
o USA
o Canada
• Europe
o UK
o France
o Germany
o Italy
o Spain
o Norway
o Russia
• Asia Pacific
o China
o India
o Japan
o South Korea
o Australia
o Malaysia
o Indonesia
o Vietnam
• South America
o Mexico
o Brazil
o Argentina
• Middle East and Africa
o GCC Countries
o South Africa
o Nigeria
o Egypt
Key players operating in Global Transthyretin Amyloidosis Treatment Market

• Alnylam Pharmaceuticals, Inc.
• Pfizer, Inc.
• GlaxoSmithKline Plc.
• Ionis Pharmaceuticals, Inc.
• Eidos Therapeutics
• SOM Innovation Biotech, S.L.
• Arcturus Therapeutics
• Merck & Co.
• AstraZeneca plc.
• Prothena Corporation plc.
• Bellus Health Inc.
For More Information Visit @: https://www.maximizemarketresearch.com/

This Report Is Submitted By :Maximize Market Research Company
Customization of the report:
Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research:
Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
Contact info:
Name: LumawantGodage
Organization Address: MAXIMIZE MARKET RESEARCH PVT. LTD.
Email: sales@maximizemarketresearch.com
Address:Pune, Maharashtra 411051, India.
Contact: +919607195908